The main reason for this week's decline is that Moderna lowered its 2025 full-year revenue guidance, and by a wide margin.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback